DRR168603
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.540
- ANGIOGENESIS+0.510
- INFLAMMATORY_RESPONSE+0.470
- ALLOGRAFT_REJECTION+0.450
- KRAS_SIGNALING_UP+0.350
- COMPLEMENT+0.340
- IL6_JAK_STAT3_SIGNALING+0.340
- G2M_CHECKPOINT+0.330
- E2F_TARGETS+0.290
- TNFA_SIGNALING_VIA_NFKB+0.290
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.410
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.380
- P53_PATHWAY-0.360
- GLYCOLYSIS-0.340
- PEROXISOME-0.330
- ADIPOGENESIS-0.320
- PROTEIN_SECRETION-0.270
- DNA_REPAIR-0.250
- FATTY_ACID_METABOLISM-0.250
- MYC_TARGETS_V1-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R263 | — | — | 0.881 |
| 2 | c56e13bb-f1b0-4ee3-85c1-807c7c3bcef9 | — | — | 0.879 |
| 3 | SRR23303766 | — | — | 0.863 |
| 4 | ULC0085T_S41 | — | cohortA1 | 0.847 |
| 5 | SRR12475140 | — | — | 0.827 |
| 6 | b3f7d666-c19c-4dd3-94b7-b85877c8ea28 | — | — | 0.817 |
| 7 | SRR25043625 | — | — | 0.792 |
| 8 | DRR168533 | — | — | 0.785 |
| 9 | GSM5359446 | — | — | 0.779 |
| 10 | ERR2278875 | — | — | 0.762 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.540 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.510 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.470 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.450 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.350 | Inavolisib | — uncovered |
| COMPLEMENT | 0.340 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.340 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.330 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.290 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.290 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.280 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.270 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.250 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.210 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.170 | Inavolisib | — uncovered |
| COAGULATION | 0.160 | Binimetinib | — uncovered |
| UV_RESPONSE_DN | 0.120 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.050 | Idelalisib | — uncovered |